吸入抗生物質の世界市場レポート 2025年

吸入抗生物質の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.1％で23億7,000万米ドルに成長します。予測期間の成長は、研究開発への投資拡大、臨床応用の拡大、個別化医療への注目の高まり、薬剤製剤の進歩、抗生物質耐性への懸念の継続などに起因すると考えられます。予測期間中の主な動向としては、製剤の継続的な革新、患者中心のアプローチ、呼吸器系の健康に関する研究の増加、標的治療へのシフト、ドラッグデリバリーシステムの進歩などが挙げられます。

呼吸器疾患の有病率の上昇は、今後数年間の吸入抗生物質市場の成長を促進すると予測されます。呼吸器疾患は肺や気道に害を与え、呼吸を困難にします。吸入抗生物質は肺機能を改善し、肺の健康状態の低下を防ぎ、増悪の間隔を延ばし、嚢胞性線維症患者の生活の質を高めます。例えば、英国の政府機関であるUK Health Security Agencyの報告によると、2023年前半の英国における結核患者数は、2022年の同時期と比較して7％増加しました。このように、呼吸器疾患の罹患率の上昇が吸入抗生物質市場を牽引する重要な要因となっています。

病院内での需要の高まりが、今後の吸入抗生物質市場を押し上げると予想されます。病院は、病気や怪我をした人々に治療、ケア、サービスを提供するために設計されたヘルスケア施設です。吸入抗生物質は、腸内細菌叢への影響を最小限に抑え、治療計画を調整し、患者のコンプライアンスを高め、入院率を下げるのに役立つため、特に呼吸器感染症の治療など、病院環境で活用されています。例えば、米国を拠点とする非営利団体である米国ヘルスケア協会の報告書によると、2023年5月の米国の病院数は6,129であり、前年の6,093病院から0.591％増加しています。その結果、病院における需要の高まりが吸入抗生物質市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の吸入抗生物質PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の吸入抗生物質市場：成長率分析
• 世界の吸入抗生物質市場の実績：規模と成長, 2019-2024
• 世界の吸入抗生物質市場の予測：規模と成長, 2024-2029, 2034F
• 世界の吸入抗生物質総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の吸入抗生物質市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エアロゾルまたは定量吸入器
• 乾燥粉末製剤
• スプレー
• その他のタイプ
• 世界の吸入抗生物質市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺炎
• 喘息
• 気管支炎
• その他の用途
• 世界の吸入抗生物質市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• その他のエンドユーザー
• 世界の吸入抗生物質市場：エアロゾルまたは定量吸入器のタイプ別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レボフロキサシン吸入液
• トブラマイシン吸入液
• アズトレオナム吸入液
• 世界の吸入抗生物質市場：乾燥粉末製剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乾燥粉末トブラマイシン
• 乾燥粉末コリスチン
• 世界の吸入抗生物質市場：スプレーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質の鼻スプレー
• 吸入抗生物質溶液
• 世界の吸入抗生物質市場：その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ネブライザーによる抗生物質
• 鼻腔内抗生物質

第7章 地域別・国別分析

• 世界の吸入抗生物質市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の吸入抗生物質市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 吸入抗生物質市場：競合情勢
• 吸入抗生物質市場：企業プロファイル
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Lupin Limited Overview, Products and Services, Strategy and Financial Analysis
  • Insmed Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Savara Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Joincare Pharmaceutical Group Industry Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Pharmaxis Ltd.
• Teva Pharmaceutical Industries Ltd.
• Raptor Pharmaceutical Corporation
• Altan Pharma Limited
• Cipla Limited
• Novartis AG
• Bayer AG
• Pfizer Inc.
• Aridis Pharmaceuticals
• Bayer HealthCare
• Nektar Therapeutics
• Parion Sciences Inc.
• Zambon Group
• Transave Inc.
• Alitair Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 吸入抗生物質市場2029：新たな機会を提供する国
• 吸入抗生物質市場2029：新たな機会を提供するセグメント
• 吸入抗生物質市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Inhaled antibiotics serve as medication specifically targeted for respiratory issues, effectively enhancing survival rates and contributing to improvements in lung function. These medications have proven instrumental in delaying lung function deterioration, extending intervals between exacerbations, and elevating overall quality of life.

Diverse types of inhaled antibiotics are available, including aerosol or metered dose inhalers, dry powder formulations, sprays, and other variations. The metered-dose inhaler (MDI) stands as a frequently utilized device for delivering inhaled respiratory medications. These antibiotics find applications across a spectrum of respiratory conditions like pneumonia, asthma, bronchitis, among others, catering to the needs of hospitals and various other healthcare settings.

The inhaled antibiotics market research report is one of a series of new reports from The Business Research Company that provides inhaled antibiotics market statistics, including inhaled antibiotics industry global market size, regional shares, competitors with an inhaled antibiotics market share, detailed inhaled antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the inhaled antibiotics industry. This inhaled antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhaled antibiotics market size has grown strongly in recent years. It will grow from $1.56 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to regulatory support and approvals, shift from systemic to targeted delivery, rise in antibiotic resistance, increase in respiratory infections.

The inhaled antibiotics market size is expected to see strong growth in the next few years. It will grow to $2.37 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to growing investments in research and development, expansion of clinical applications, increasing focus on personalized medicine, advancements in drug formulations, continued antibiotic resistance concerns. Major trends in the forecast period include continued innovation in formulations, patient-centric approach, increased research in respiratory health, shift towards targeted therapies, advancements in drug delivery systems.

The rising prevalence of respiratory diseases is anticipated to drive the growth of the inhaled antibiotics market in the coming years. Respiratory diseases harm the lungs and airways, making it difficult for individuals to breathe. Inhaled antibiotics improve lung function, help prevent a decline in lung health, prolong the intervals between exacerbations, and enhance the quality of life for patients with cystic fibrosis. For example, a report from the UK Health Security Agency, a government organization in the UK, indicated that the number of tuberculosis (TB) cases in England increased by 7% in the first half of 2023 compared to the same period in 2022. Thus, the rising incidence of respiratory diseases is a key factor driving the inhaled antibiotics market.

The growing demand within hospitals is expected to boost the inhaled antibiotics market in the future. Hospitals are healthcare facilities designed to provide medical treatment, care, and services to individuals who are ill or injured. Inhaled antibiotics are utilized in hospital settings, especially for treating respiratory infections, as they help minimize the impact on gut microbiota, tailor treatment plans, enhance patient compliance, and lower hospitalization rates. For instance, a report from the American Health Care Association, a nonprofit organization based in the US, noted that there were 6,129 hospitals in the United States in May 2023, marking a 0.591% increase from the 6,093 hospitals the previous year. Consequently, the rising demand in hospitals is fueling the growth of the inhaled antibiotics market.

Investments in the development of inhaled antibiotics represent a significant trend gaining traction in the inhaled antibiotics market. Major pharmaceutical companies are committing resources to the development of inhaled antibiotics to maintain their competitive edge. For example, in August 2023, Spexis AG, a biopharmaceutical company based in Switzerland, announced a $2.5 million capital commitment aimed at financing the U.S. commercialization of colistimethate sodium, an inhaled antibiotic intended for cystic fibrosis patients with Pseudomonas aeruginosa infections. This funding supports commercialization efforts projected at $90 million, with potential peak sales reaching $300 million. Additionally, it facilitates the initiation of a Phase III safety and efficacy study for the antibiotic's application in cystic fibrosis treatment.

Innovative products like Breyna are being strategically introduced by major players in the inhaled antibiotics market to drive revenue growth. Breyna, an inhalation aerosol combining formoterol fumarate dihydrate and budesonide, effectively manages symptoms associated with asthma and persistent lung diseases. Viatris Inc., in partnership with Kindeva Drug Delivery L.P., successfully launched Breyna in July 2023. This FDA-approved generic version of AstraZeneca's Symbicort is supplied as a metered-dose inhaler and comes in two strengths, catering to patients' varying needs, reflecting the market's focus on innovation and tailored therapeutic solutions.

In January 2024, Essential Pharma, a pharmaceutical company based in the UK, acquired Colobreathe from Teva Laboratories UK Limited for an undisclosed sum. This acquisition signifies Essential Pharma's entry into the rare disease sector, enhancing its portfolio with treatments specifically designed for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. With this deal, the company aims to secure ongoing access to essential medications throughout Europe. Teva Laboratories UK Limited is recognized as a UK-based manufacturer of inhaled antibiotics.

Major companies operating in the inhaled antibiotics market are Gilead Sciences Inc., Lupin Limited, Insmed Inc., Savara Inc., Joincare Pharmaceutical Group Industry Co. Ltd., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical Corporation, Altan Pharma Limited, Cipla Limited, Novartis AG, Bayer AG, Pfizer Inc., Aridis Pharmaceuticals, Bayer HealthCare, Nektar Therapeutics, Parion Sciences Inc., Zambon Group, Transave Inc., Alitair Pharmaceuticals, Synspira Therapeutics Inc., AIT Therapeutics Inc., Polyphor AG, OptiNose Inc.

North America was the largest region in the inhaled antibiotics market share in 2024. The regions covered in the inhaled antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the inhaled antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inhaled antibiotics market consists of sales of jet nebulizers, ultrasonic nebulizers, mesh inhalers, and soft mist inhalers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhaled Antibiotics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhaled antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhaled antibiotics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inhaled antibiotics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Aerosol Or Metered Dose Inhaler; Dry Powder Formulation; Spray; Other Types
• 2) By Application: Pneumonia; Asthma; Bronchitis; Other Applications
• 3) By End-User: Hospitals; Other End Users
• Subsegments:
• 1) By Aerosol Or Metered Dose Inhaler: Levofloxacin Inhalation Solution; Tobramycin Inhalation Solution; Aztreonam Inhalation Solution
• 2) By Dry Powder Formulation: Dry Powder Tobramycin; Dry Powder Colistin
• 3) By Spray: Antibiotic Nasal Sprays; Inhaled Antibiotic Solutions
• 4) By Other Types: Nebulized Antibiotics; Intranasal Antibiotics
• Companies Mentioned: Gilead Sciences Inc.; Lupin Limited; Insmed Inc.; Savara Inc.; Joincare Pharmaceutical Group Industry Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inhaled Antibiotics Market Characteristics

3. Inhaled Antibiotics Market Trends And Strategies

4. Inhaled Antibiotics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Inhaled Antibiotics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Inhaled Antibiotics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Inhaled Antibiotics Market Growth Rate Analysis
• 5.4. Global Inhaled Antibiotics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Inhaled Antibiotics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Inhaled Antibiotics Total Addressable Market (TAM)

6. Inhaled Antibiotics Market Segmentation

• 6.1. Global Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aerosol or Metered Dose Inhaler
• Dry Powder Formulation
• Spray
• Other Types
• 6.2. Global Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pneumonia
• Asthma
• Bronchitis
• Other Applications
• 6.3. Global Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Other End Users
• 6.4. Global Inhaled Antibiotics Market, Sub-Segmentation Of Aerosol Or Metered Dose Inhaler, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levofloxacin Inhalation Solution
• Tobramycin Inhalation Solution
• Aztreonam Inhalation Solution
• 6.5. Global Inhaled Antibiotics Market, Sub-Segmentation Of Dry Powder Formulation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Powder Tobramycin
• Dry Powder Colistin
• 6.6. Global Inhaled Antibiotics Market, Sub-Segmentation Of Spray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotic Nasal Sprays
• Inhaled Antibiotic Solutions
• 6.7. Global Inhaled Antibiotics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nebulized Antibiotics
• Intranasal Antibiotics

7. Inhaled Antibiotics Market Regional And Country Analysis

• 7.1. Global Inhaled Antibiotics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Inhaled Antibiotics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inhaled Antibiotics Market

• 8.1. Asia-Pacific Inhaled Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inhaled Antibiotics Market

• 9.1. China Inhaled Antibiotics Market Overview
• 9.2. China Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inhaled Antibiotics Market

• 10.1. India Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inhaled Antibiotics Market

• 11.1. Japan Inhaled Antibiotics Market Overview
• 11.2. Japan Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inhaled Antibiotics Market

• 12.1. Australia Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inhaled Antibiotics Market

• 13.1. Indonesia Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inhaled Antibiotics Market

• 14.1. South Korea Inhaled Antibiotics Market Overview
• 14.2. South Korea Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inhaled Antibiotics Market

• 15.1. Western Europe Inhaled Antibiotics Market Overview
• 15.2. Western Europe Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inhaled Antibiotics Market

• 16.1. UK Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inhaled Antibiotics Market

• 17.1. Germany Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inhaled Antibiotics Market

• 18.1. France Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inhaled Antibiotics Market

• 19.1. Italy Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inhaled Antibiotics Market

• 20.1. Spain Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inhaled Antibiotics Market

• 21.1. Eastern Europe Inhaled Antibiotics Market Overview
• 21.2. Eastern Europe Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inhaled Antibiotics Market

• 22.1. Russia Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inhaled Antibiotics Market

• 23.1. North America Inhaled Antibiotics Market Overview
• 23.2. North America Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inhaled Antibiotics Market

• 24.1. USA Inhaled Antibiotics Market Overview
• 24.2. USA Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inhaled Antibiotics Market

• 25.1. Canada Inhaled Antibiotics Market Overview
• 25.2. Canada Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inhaled Antibiotics Market

• 26.1. South America Inhaled Antibiotics Market Overview
• 26.2. South America Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inhaled Antibiotics Market

• 27.1. Brazil Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inhaled Antibiotics Market

• 28.1. Middle East Inhaled Antibiotics Market Overview
• 28.2. Middle East Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inhaled Antibiotics Market

• 29.1. Africa Inhaled Antibiotics Market Overview
• 29.2. Africa Inhaled Antibiotics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Inhaled Antibiotics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Inhaled Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inhaled Antibiotics Market Competitive Landscape And Company Profiles

• 30.1. Inhaled Antibiotics Market Competitive Landscape
• 30.2. Inhaled Antibiotics Market Company Profiles
  • 30.2.1. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Insmed Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Savara Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Joincare Pharmaceutical Group Industry Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Inhaled Antibiotics Market Other Major And Innovative Companies

• 31.1. Pharmaxis Ltd.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Raptor Pharmaceutical Corporation
• 31.4. Altan Pharma Limited
• 31.5. Cipla Limited
• 31.6. Novartis AG
• 31.7. Bayer AG
• 31.8. Pfizer Inc.
• 31.9. Aridis Pharmaceuticals
• 31.10. Bayer HealthCare
• 31.11. Nektar Therapeutics
• 31.12. Parion Sciences Inc.
• 31.13. Zambon Group
• 31.14. Transave Inc.
• 31.15. Alitair Pharmaceuticals

32. Global Inhaled Antibiotics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inhaled Antibiotics Market

34. Recent Developments In The Inhaled Antibiotics Market

35. Inhaled Antibiotics Market High Potential Countries, Segments and Strategies

• 35.1 Inhaled Antibiotics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Inhaled Antibiotics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Inhaled Antibiotics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer